World Wires · story 18445 · unverified · 1 source(s)

Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer

Media Release

Open in the desk

Coverage

• Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer GlobeNewswire: public companies · tier D · clear net · 2026-10-03 19:40 UTC

What this site indexes